Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695435 · ClinicalTrials.gov registry record · Phase 1
Tobramycin Tear Concentrations
A Phase 1 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00695435: Completed Phase 1 study, sponsored by Alcon Research.
NCT00695435 is a Phase 1 study that has completed, run by Alcon Research. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00695435, a Phase 1 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
Primary Outcome
Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject's right eye for each treatment period.
Interventions
- DRUG TOBRADEX Ophthalmic Suspension
- DRUG Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
- DRUG TOBREX Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-06 |
| Phase | Phase 1 |
What the finished NCT00695435 record still lists
NCT00695435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which TOBRADEX Ophthalmic Suspension is the first listed.
NCT00695435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00695435 about?
NCT00695435 is a clinical study titled "Tobramycin Tear Concentrations". To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
What is the current status of trial NCT00695435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2008-06.
What interventions are being tested in trial NCT00695435?
The interventions under investigation include: TOBRADEX Ophthalmic Suspension (DRUG), Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension (DRUG), TOBREX Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT00695435?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00695435's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia